Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.26 Bil Enterprise Value: 13.31 Bil PE Ratio: 70.58 PB Ratio: 2.82 GF Score: 62/100

Biomarin Pharmaceutical Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript

Nov 15, 2021 / 09:00PM GMT
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone. My name is Gena Wang. I'm SMID Cap Biotech Analyst at Barclays. Welcome to our fifth Gene Editing & Gene Therapy Summit.

It is my great pleasure to introduce our next speaker, Hank Fuchs, President Worldwide R&D from BioMarin. Hank, maybe I'll hand over to give a brief overview, then I will dive into the Q&A.

Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development

Thanks very much, Gena. It's great to be here. and we appreciate the opportunity with just a few weeks remaining in 2021, we look forward to 2022 with great excitement. As the Head of R&D, I'm very pleased with the execution of our pipeline pivot from predominantly ultra-rare disorders to products that address more prevalently affected conditions. Our mission to translate genetic discoveries and transformative medicines has not changed, but the ability to leverage our deep foundational knowledge is changing the breadth and depth of our next

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot